Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam as their first adjunctive ASD

References

• Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821–825.
   PubMed Web of Science ®Google Scholar
• Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34(3):453–468.
   PubMed Web of Science ®Google Scholar
• Clinical Brief. Examining the economic impact and implications of epilepsy. Am J Manag Care. 2020 [cited 2021 Apr 16]. Available from: https://ajmc.s3.amazonaws.com/_media/_pdf/A948_ClinicalBrief_pdf.pdf
   Google Scholar
• de Biase S, Nilo A, Bernardini A, et al. Timing use of novel anti-epileptic drugs: is earlier better? Expert Rev Neurother. 2019;19(10):945–954.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):74–81.
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563.
   PubMed Web of Science ®Google Scholar
• Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919–926.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000b;9(7):464–468.
   PubMed Web of Science ®Google Scholar
• Ghaffari-Rafi A, Leon-Rojas J. Investigatory pathway and principles of patient selection for epilepsy surgery candidates: a systematic review. BMC Neurol. 2020;20(1):100.
   PubMed Web of Science ®Google Scholar
• Mula M. Third generation antiepileptic drug monotherapies in adults with epilepsy. Expert Rev Neurother. 2016;16(9):1087–1092. Epub 2016 Jun 8.
   PubMed Web of Science ®Google Scholar
• Santulli L, Coppola A, Balestrini S, et al. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016;107:211–219. Epub 2016 Mar 16.
   PubMed Web of Science ®Google Scholar
• Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587–2600.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Cagnetti C, et al. Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy. Core Evid. 2018;13:21–31.
   PubMed Web of Science ®Google Scholar
• Khalegi F, Nemec II. EC. Brivaracetam (briviact): a novel adjunctive therapy for partial-onset seizures. P T. 2017;42(2):92–96.
   PubMedGoogle Scholar
• Andermann E, Biton V, Benbadis SR, et al. Psychiatric and cognitive adverse events: a pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures. Epilepsy Behav. 2018;82:119–127.
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals Inc. APTIOM® (eslicarbazepine acetate) Prescribing Information. 2019 [cited 2021 Apr 16]. Available from: https://www.aptiom.com/Aptiom-Prescribing-Information.pdf
   Google Scholar
• UCB. BRIVIACT® (brivaracetam) Prescribing Information. 2018 [cited 2021 Apr 16]. Available from: https://www.briviact.com/briviact-PI.pdf
   Google Scholar
• Hixson J, Gidal B, Pikalov A, et al. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. Epilepsy Res. 2021;171:106561.
   PubMed Web of Science ®Google Scholar
• Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015;15:245–266.
   PubMed Web of Science ®Google Scholar
• Begley CE, Durgin TL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia. 2015;56(9):1376–1387.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia. 2010;51(5):838–844.
   PubMed Web of Science ®Google Scholar
• Mehta D, Davis M, Epstein AJ, et al. Impact of early initiation of eslicarbazepine acetate on economic outcomes among patients with focal seizure: results from retrospective database analyses. Neurol Ther. 2020;9(2):585–598.
   PubMed Web of Science ®Google Scholar
• Mehta D, Davis M, Epstein AJ, et al. Comparative economic outcomes in patients with focal seizure initiating first-line eslicarbazepine acetate monotherapy versus generic antiseizure drugs. Clinicoecon Outcomes Res. 2021;13:251–261.
   PubMed Web of Science ®Google Scholar
• French J. Will brivaracetam help my patient? Only time will tell. Epilepsy Curr. 2017;17(1):35–36.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Summary of the HIPAA privacy rule. Washington (DC): US Department of Health and Human Services. 2013 [cited 2021 Apr 16]. Available from: https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html
   Google Scholar
• Office for Human Research Protections 2018 Requirements. 2018 common rule. Rockville (MD): Office for Human Research Protections 2018 Requirements. 2018 [cited 2021 Apr 16]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/revised-common-rule-regulatory-text/index.html
   Google Scholar
• US Bureau of Economic Analysis. Table 1.1.4. Price indexes for gross domestic product. Suitland (MD): US Bureau of Economic Analysis. 2021 [cited 2021 Apr 16]. Available from: https://apps.bea.gov/iTable/iTable.cfm?reqid=19&step=2
   Google Scholar
• Linden A, Adams JL. Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation. J Eval Clin Pract. 2011;17(6):1231–1238.
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Cameron AC, Miller DL. A practitioner’s guide to cluster-robust inference. J Human Resources. 2015;50(2):317–372.
   Web of Science ®Google Scholar
• Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Statist Med. 2000;19(9):1141–1164.
   PubMed Web of Science ®Google Scholar
• Poi BP. From the help desk: some bootstrapping techniques. The Stata Journal. 2004;4(3):312–328.
   Web of Science ®Google Scholar
• Wood M. Bootstrapped confidence intervals as an approach to statistical inference. Organ Res Methods. 2005;8(4):454–470.
   Web of Science ®Google Scholar
• Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8):S84–S90.
   PubMed Web of Science ®Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66.
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56.
   PubMed Web of Science ®Google Scholar
• Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898.
   PubMed Web of Science ®Google Scholar
• Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(A):165–168.
   PubMed Web of Science ®Google Scholar
• Steinig I, von Podewils F, Möddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58(7):1208–1216.
   PubMed Web of Science ®Google Scholar
• Hirsch M, Hintz M, Specht A, et al. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98–103.
   PubMed Web of Science ®Google Scholar
• Mäkinen J, Rainesalo S, Peltola J. Transition from oxcarbazepine to eslicarbazepine acetate: a single center study. Brain Behav. 2017;7(3):e00634.
   PubMed Web of Science ®Google Scholar
• Rocamora R, Peltola J, Assenza G, et al. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. Seizure. 2020;75:121–128.
   PubMed Web of Science ®Google Scholar
• Williams GR, Chandra R, Wang J, et al. Healthcare resource utilization among patients with focal seizure initiating eslicarbazepine acetate after historical use of widely used first- or second-generation antiseizure drugs. Paper presented at the AES Meeting 2020; 2020 December 4–8; Seattle, WA.
   Google Scholar
• Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol. 2016;12(2):106–116.
   PubMed Web of Science ®Google Scholar
• Schiltz NK, Koroukian SM, Singer ME, et al. Disparities in access to specialized epilepsy care. Epilepsy Res. 2013;107(1–2):172–180.
   PubMed Web of Science ®Google Scholar
• Szaflarski M, Wolfe JD, Tobias JGS, et al. Poverty, insurance, and region as predictors of epilepsy treatment among US adults. Epilepsy Behav. 2020;107:107050.
   PubMed Web of Science ®Google Scholar
• Toledano R, Jovel CE, Jimenez-Huete A, et al. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: experience from a multicenter, observational study. Epilepsy Behav. 2017;73:173–179.
   PubMed Web of Science ®Google Scholar
• French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141–158.
   PubMedGoogle Scholar
• Jalihal V, Shankar R, Henley W, et al. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav. 2018;80:365–369.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee H, Kim DW. Switching antiepileptic drugs to once-daily dosing regimens in epilepsy patients. Acta Neurol Scand. 2021;143(1):51–55.
   PubMed Web of Science ®Google Scholar
• Ferrari CM, de Sousa RM, Castro LH. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 2013;22(5):384–389.
   PubMed Web of Science ®Google Scholar